Kristin Brooks02.24.21
Altasciences has contributed to the recent FDA approval of Vibegron, a beta-3 adrenergic receptor (β3) agonist for the treatment of overactive bladder, conducting multiple early phase clinical trialsfor Urovant Sciences.
Altasciences provided clinical support for two drug-drug interaction studies and a bioavailability trial, conducted in 2018 and 2019, in healthy subjects. These trials were supported by Altasciences’ data services team, who performed the full data management and reporting for the associated clinical studies.
“We take tremendous pride in contributing to the FDA approval of much-needed medicines that improve the health and wellbeing of patients,” said Amy Denvir, General Manager at Altasciences’ Kansas clinical pharmacology unit. “Working with Urovant Sciences on this program has been a pleasure, and we are delighted to see it come to fruition.”
Altasciences is a mid-size contract research organization offering preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services.
Altasciences provided clinical support for two drug-drug interaction studies and a bioavailability trial, conducted in 2018 and 2019, in healthy subjects. These trials were supported by Altasciences’ data services team, who performed the full data management and reporting for the associated clinical studies.
“We take tremendous pride in contributing to the FDA approval of much-needed medicines that improve the health and wellbeing of patients,” said Amy Denvir, General Manager at Altasciences’ Kansas clinical pharmacology unit. “Working with Urovant Sciences on this program has been a pleasure, and we are delighted to see it come to fruition.”
Altasciences is a mid-size contract research organization offering preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services.
